Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV

Core Insights - Theratechnologies Inc. announced data highlighting the link between excess visceral abdominal fat (EVAF) and cardiovascular disease (CVD) risk in people with HIV, along with the potential of tesamorelin to mitigate this risk [1][2] VAMOS Study Findings - The VAMOS study, a multicenter observational study, found that 58% of participants with HIV had EVAF, with a mean visceral fat area of 148 cm² [2][4] - Higher EVAF was associated with increased 10-year atherosclerotic cardiovascular disease (ASCVD) risk and traditional risk factors such as insulin resistance and lipid levels [3][4] - A positive correlation was observed between EVAF and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) scores, as well as triglyceride:high-density lipoprotein (TG:HDL) ratios [2][3] Tesamorelin Impact on CVD Risk - Data from two phase 3 studies indicated that tesamorelin treatment led to a modest reduction in 10-year ASCVD risk scores, with an estimated change of -0.4% [5][6] - The reduction in CVD risk was more significant among participants with higher baseline risk, primarily driven by decreases in total cholesterol [5][6] - The study involved 543 participants, with 44% on lipid-lowering therapies, 37% on antihypertensive treatment, and 18% on diabetes medications [5]